Much of cell behavior is governed by the actions of biomolecular condensates: building block molecules that glom together and ...

Among participants who met the core RESTORE-ALS Trial criteria (e.g., baseline serum NfL > 33 pg/mL, TRICALS risk score range between –6.5 and –2.5, baseline slow vital capacity > 60%, and symptom ...

Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the ...

AKGsOVIHAMS, a leading healthcare institution, has marked progress in treating ALS using integrative medicine. Known for combining conventional and alternative therapies, the institute has shown ...

Startup Cognixion, which has developed a noninvasive brain-computer interface, has begun a clinical trial for patients with ...

Positron emission tomography (PET) is a nuclear imaging technique used to diagnose conditions such as cancer. An innovative ...

In this week’s InnovationRx newsletter, the worsening measles outbreak, a noninvasive brain-computer implant, replacing heart ...

Despite its increasing prevalence, a painful condition called bladder pain syndrome, or interstitial cystitis, remains ...

Recent studies have highlighted a link between amyotrophic lateral sclerosis (ALS) and gut microbiota. This prospective study aimed to evaluate the effects of electroacupuncture combined with Chinese ...

Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.

On March 5, 2025, Denali Therapeutics ( DNLI) Inc. provided an update that further analyses from Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment ...